Trial Profile
A Pilot Study of Dasatinib for Relapsed or Refractory ABL1/PDGFRB Rearrangemennt Positive Ph-like Acute Lymphoblasic Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms D-APPLE
- 12 Feb 2015 New trial record